Mouse Anti-VACV L1 Recombinant Antibody (clone 7D11) (CAT#: FAMAB-0715WJ)

This product is a mouse monoclonal antibody that is specific for VACV L1. This antibody can be used in a variety of applications, such as ELISA, WB, Neut, IF.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA
ELISA

Figure 1 Binding to purified VACV.

Figure 1 Binding to purified VACV.

Serial twofold dilutions of mAb-7D11, 7D11-F(ab')2, and 7D11-Fab or negative control antibody mAb-3D7 starting at 80 μg/ml were tested for the capacity to bind purified virus by VACV-infected-cell lysate ELISA. Some antigen-coated plates were treated with UV light (grey dashed lines) before incubation with mAb-7D11 (MAb-7D11 UV).

Su, H. P., Golden, J. W., Gittis, A. G., Hooper, J. W., & Garboczi, D. N. (2007). Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology, 368(2), 331-341.

ELISA

Figure 2 Binding to recombinant L1.

Figure 2 Binding to recombinant L1.

Serial twofold dilutions of mAb-7D11, 7D11-F(ab')2, and 7D11-Fab or negative control antibody mAb-10F10 (anti-A33) starting at 80 μg/ml were tested for the capacity to bind recombinant L1 by ELISA. Purified L1 at 100 ng/well was untreated or treated with UV light (grey dashed lines). The x-axes in A and B are plotted on log(2) scales.

Su, H. P., Golden, J. W., Gittis, A. G., Hooper, J. W., & Garboczi, D. N. (2007). Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology, 368(2), 331-341.

Neut

Figure 3 VACV was incubated with purified mAb-7D11, 7D11-F(ab′)2, or 7D11-Fab at 37°C for 1 h.

Figure 3 VACV was incubated with purified mAb-7D11, 7D11-F(ab′)2, or 7D11-Fab at 37°C for 1 h.

Virus-antibody mixtures or untreated virus were adsorbed on to confluent monolayers of BSC-1 cells, followed the addition of a semi-solid overlay of 1.5% methylcellulose as described in Methods. After 4 d, plaques were counted after staining with 3% crystal violet. The percent neutralization of plaque formation by antibody addition relative to untreated virus is plotted versus concentration on a log(2) scale.

Su, H. P., Golden, J. W., Gittis, A. G., Hooper, J. W., & Garboczi, D. N. (2007). Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology, 368(2), 331-341.

Neut

Figure 4 Virus-antibody mixtures or untreated virus were adsorbed on to confluent monolayers of BSC-1 cells, followed the addition of a semi-solid overlay of 1.5% methylcellulose.

Figure 4 Virus-antibody mixtures or untreated virus were adsorbed on to confluent monolayers of BSC-1 cells, followed the addition of a semi-solid overlay of 1.5% methylcellulose.

After 4 d, plaques were counted after staining with 3% crystal violet. The percent neutralization of plaque formation by antibody addition relative to untreated virus is plotted versus concentration on a log(2) scale.

Su, H. P., Golden, J. W., Gittis, A. G., Hooper, J. W., & Garboczi, D. N. (2007). Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology, 368(2), 331-341.

Neut

Figure 5 Confluent monolayers of BSC-1 cells were chilled on ice and incubated with ~50 PFU of VACV strain IHD-J per well for 1 h at 4°C.

Figure 5 Confluent monolayers of BSC-1 cells were chilled on ice and incubated with ~50 PFU of VACV strain IHD-J per well for 1 h at 4°C.

After adsorption, virus was removed and mAb-7D11 or 7D11-Fab was added to the wells at the indicated concentrations for 1 h at 4°C. After incubation, anti-Fab antibodies (1:100) were added to the wells of some samples for another 1 h at 4°C. Plates were then incubated at 37°C and plaques were visualized as described in A.

Su, H. P., Golden, J. W., Gittis, A. G., Hooper, J. W., & Garboczi, D. N. (2007). Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology, 368(2), 331-341.

FC

Figure 6 Interaction of anti-L1 monoclonal antibodies with mutated L1.

Figure 6 Interaction of anti-L1 monoclonal antibodies with mutated L1.

COS-7 cells were transfected with pWRG/TPA-L1R (black line), pWRG/TPA-L1R D35N (grey line), or empty pWRG vector (solid grey). Cells were incubated with 1:100 dilutions of mAb-7D11 (anti-L1). A anti-mouse secondary antibody (1:500) conjugated to Alexa 488 fluorochrome was added and cells were analyzed by flow cytometry using a FACSCalibur flow cytometer. For each sample, 10,000 cells were counted.

Su, H. P., Golden, J. W., Gittis, A. G., Hooper, J. W., & Garboczi, D. N. (2007). Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology, 368(2), 331-341.

IF

Figure 7 Cell surface expression of modified L1 proteins determined by confocal microscopy.

Figure 7 Cell surface expression of modified L1 proteins determined by confocal microscopy.

BS-C-1 cells were transfected with empty vector, pL1op, or psL1op and stained with anti-L1 mAb (7D11) followed by anti-mouse IgG FITC and viewed by confocal microscopy. Upper panel shows confocal fluorescent images and the lower panel shows a merge of confocal fluorescent and differential interference contrast images.

Shinoda, K., Wyatt, L. S., Irvine, K. R., & Moss, B. (2009). Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization. Virology journal, 6(1), 1-8.

FC

Figure 8 Cell surface expression of modified L1 proteins determined by flow cytometry.

Figure 8 Cell surface expression of modified L1 proteins determined by flow cytometry.

BS-C-1 cells were transfected as in panel A. After 24 h, non-permeabilized cells were incubated with MAb 7D11 followed by anti-mouse IgG antibody conjugated to fluorescein isothiocyanate, fixed with paraformaldehyde and analyzed by flow cytometry with gating on L1 positive cells.

Shinoda, K., Wyatt, L. S., Irvine, K. R., & Moss, B. (2009). Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization. Virology journal, 6(1), 1-8.


Specifications

  • Immunogen
  • Recombinant L1 proteins
  • Host Species
  • Mouse
  • Derivation
  • Hybridoma
  • Type
  • Mouse IgG
  • Specificity
  • VACV L1
  • Species Reactivity
  • VACV
  • Clone
  • 7D11
  • Applications
  • ELISA, WB, Neut, IF
  • Related Disease
  • VACV infection

Product Property

  • Purity
  • >95% as determined by SDS-PAGE
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • Vaccinia virus L1; Vaccinia virus; VACV; VV; VACV L1

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "VACV L1"

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for FAMAB-0715WJ. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare